UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended November 30, 2017

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period __________ to __________

 

Commission File Number: 000-54207

 

ChineseInvestors.COM, Inc.

(Exact name of registrant as specified in its charter)

 

Indiana   35-2089868

(State or Other Jurisdiction of

Incorporation or Organization)

 

(IRS Employer

Identification Number)

 

227 W Valley Blvd. STE 208A San Gabriel, CA 91776

Wei Wang, Chief Executive Officer (800)958-8561

 

Copies to: Michael E. Shaff, Esq. , Irvine Venture Law Firm, LLP

19900 MacArthur Boulevard, Suite 530, Irvine, CA 92612 Telephone (949) 660-7700

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No  o  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨   Accelerated filer   ¨
       
Non-accelerated filer   ¨   (Do not check if a smaller reporting company)   Smaller reporting company   x  
             
Emerging growth company    x  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes   ¨     No   x

 

As of November 30, 2017 there were outstanding 22,923,560 shares of the issuer’s common stock, par value $0.001 per share and 465,000 shares of the issuer’s Series 2012 preferred stock, par value $0.001 per share and 776,000 shares of the issuer’s Series A-2014 preferred stock, par value $0.001 per share and 2,091,958 shares of the issuer’s Series C-2016 preferred stock, par value $0.001 per share and 2,750,000 shares of the Series D-2017 preferred stock, par value $0.001 per share.

 

 

     
 

 

CHINESEINVESTORS.COM, INC AND SUBSIDIARIES.

 

FORM 10-Q for the Quarter Ended November 30, 2017

 

INDEX

 

    Page  
PART I - FINANCIAL INFORMATION
             
Item 1.   Financial Statements     3  
             
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations     17  
             
Item 3.   Quantitative and Qualitative Disclosures About Market Risk     19  
             
Item 4.   Controls and Procedures     19  
             
PART II - OTHER INFORMATION
             
Item 1.   Legal Proceedings     20  
             
Item 2.   Unregistered Sale of Equity Securities and Use of Proceeds     20  
             
Item 3.     Defaults Upon Senior Securities        20  
             
Item 4.   Mine Safety Disclosures     20  
             
Item 5.   Other Information     20  
             
Item 6.   Exhibits       20  
             
Signatures     21  

 

 

 

 

  2  
 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements. 

 

CHINESEINVESTORS.COM, INC AND SUBSIDIARIES

BALANCE SHEETS

Expressed in U.S. Dollars  

 

    (Unaudited)        
    November 30,     May 31,  
    2017     2017  
Assets                
Current assets                
Cash and cash equivalents   $ 1,547,361     $ 1,770,729  
Accounts receivable, net     47,215       8,627  
Investments, available for sale, in affiliate     69,691       72,166  
Investments, available for sale     1,348,691       656,909  
Inventory     80,688       7,690  
Other current assets     304,502       271,401  
Total current assets     3,398,148       2,787,522  
                 
Non-current assets                
Investment-affiliate     250,000       250,000  
Property and equipment, net     46,514       53,032  
Website development, net     101,833       81,687  
Total non-current assets     398,347       384,719  
                 
Total assets   $ 3,796,495     $ 3,172,241  
                 
Liabilities and Stockholders’ Equity                
Current liabilities                
Accounts payable   $ 223,229     $ 303,463  
Deferred revenue     438,969       270,296  
Investor deposit           210,100  
Unearned revenue paid in stock     558,486       231,945  
Stock compensation payable     656,600        
Accrued liabilities     133,579       67,782  
Accrued dividend & interest     158,489       167,688  
Secured debt     965,140       410,000  
Embedded incentive interest     2,242       23,520  
Total current liabilities     3,136,734       1,684,794  
                 
Non-current Liabilities                
Long-term deferred revenue     136,658       96,144  
Total Non-current Liabilities     136,658       96,144  
                 
Total liabilities     3,273,392       1,780,938  
                 
Commitments and Contingencies                
Shareholders’ equity                
Preferred stock, series 2012, $0.001 par value 20,000,000 authorized, 465,000 and 615,000 were issued and outstanding at November 30, 2017 and May 31, 2017, respectively     465       615  
Preferred stock, Series A-2014, $0.001 par value 20,000,000 authorized, 776,000 and 1,770,000 were issued and outstanding at November 30, 2017 and May 31, 2017, respectively     776       1,770  
Preferred stock, Series C-2016, $0.001 par value 20,000,000 authorized, 2,091,958 and 5,000,043 were issued and outstanding at November 30, 2017 and May 31, 2017, respectively     2,092       5,000  
Preferred stock, Series D-2017, $0.001 par value 20,000,000 authorized, 2,750,000 and 0 were issued and outstanding at November 30, 2017 and May 31, 2017, respectively     2,750        
Common stock $0.001 par value 80,000,000 authorized 22,923,560 and 11,446,805 were issued and outstanding November 30, 2017 and May 31, 2017, respectively     22,924       11,448  
Additional paid-in capital     29,784,529       23,928,741  
Unrealized gain (loss) on investments     (299,159 )     (206,892 )
Foreign currency gain/(loss)     1,887        
Accumulated deficit     (28,993,161 )     (22,349,379 )
Total Shareholders' equity     523,103       1,391,303  
                 
Total liabilities and shareholders’ equity   $ 3,796,495     $ 3,172,241  

 

See accompanying notes to the financial statements

  3  
 

 

CHINESEINVESTORS.COM, INC AND SUBSIDIARIES

STATEMENT OF COMPREHENSIVE (LOSS) AND INCOME

For the Three and Six Months Ended November 30, 2017 and 2016

(Unaudited)

Expressed in U.S. Dollars

  

 

    Three Months Ended     Six Months Ended  
    November 30,     November 30,  
    2017     2016     2017     2016  
                         
Operating revenues                                
Investor relations - advertisement   $ 246,667     $ 278,850     $ 505,033     $ 369,162  
Subscription     179,333       232,094       315,596       481,323  
Sales-Hemp related products     39,603             57,568        
Other                 4,754       1,783  
Total revenue     465,603       510,944       882,951       852,268  
                                 
Cost of revenue                                
Products     15,050             19,951        
Services     385,588       220,525       658,219       449,396  
      400,638       220,525       678,170       449,396  
                                 
Gross profit (loss)     64,965       290,419       204,781       402,872  
                                 
Operating Expenses                                
General and administrative Expense     1,887,872       1,207,803       3,109,803       2,053,478  
Advertising expense     303,977       180,844       529,219       361,567  
Total operating expenses     2,191,849       1,388,647       3,639,022       2,415,045  
                                 
Net loss from operations     (2,126,884 )     (1,098,228 )     (3,434,241 )     (2,012,173 )
                                 
Other income/(expense)                                
Other income     1,715       2,285       8,875       2,585  
Interest expense     (7,693 )     (57,921 )     (14,534 )     (67,634 )
Net realized gain/(loss) on marketable equity securities           883,807             1,634,685  
Total other income (expense)     (5,978 )     828,171       (5,659 )     1,569,636  
                                 
Net loss   $ (2,132,862 )   $ (270,057 )   $ (3,439,900 )   $ (442,538 )
                                 
Preferred stock deemed dividend     (1,803,720 )           (3,048,342 )      
Preferred stock dividends     (81,283 )     (38,976 )     (155,539 )     (77,963 )
Net loss attributable to common shareholders     (4,017,865 )     (309,033 )     (6,643,781 )     (520,501 )
                                 
Earnings per share attributable to common shareholders:                                
Basic and diluted (loss) per share   $ (0.18 )   $ (0.04 )   $ (0.38 )   $ (0.07 )
Weighted average number of shares outstanding - basic & diluted     21,931,055       8,116,750       17,577,939       7,888,035  
Other comprehensive loss                                
Net unrealized loss on available for sale securities     (3,185 )     (848,577 )     (92,267 )     (2,177,433 )
                                 
Comprehensive loss attributable to common shareholders   $ (4,021,050 )   $ (1,157,610 )   $ (6,736,048 )   $ (2,697,934 )

 

 

See accompanying notes to the financial statements 

 

  4  
 

 

CHINESEINVESTORS.COM, INC AND SUBSIDIARIES

STATEMENT OF CASH FLOWS

For the Six Months Ended November 30, 2017 and 2016

(Unaudited)

Expressed in U.S. Dollars

 

    2017     2016  
Cash flows from operating activities                
Net loss   $ (3,439,900 )   $ (442,538 )
Adjustments to reconcile net loss to net cash (used in) provided by operating activities                
Non-cash revenue received as available for sale securities     (455,033 )     (230,133 )
Net realized (gain)/loss on marketable equity securities           (1,634,685 )
Foreign currency exchange loss (gain)           (699 )
Stock Compensation     724,220        
Depreciation and amortization     12,947       6,855  
Changes in operating assets and liabilities                
Accounts receivable     (38,589 )     (40,383 )
Inventory     (72,999 )      
Other current assets     (33,101 )     (2,250 )
Accounts payable     (80,233 )     25,565  
Accrued interest     (35,185 )     103,563  
Deferred revenue     209,188       451,289  
Other accrued liabilities     65,797       67,925  
Net cash (used in) operating activities     (3,142,888 )     (1,695,491 )
                 
Cash flows from investing activities                
Purchase of equipment     (26,576 )     (8,222 )
Proceeds from the sale of marketable equity securities           1,917,719  
Purchase of marketable equity securities-affiliate           (174,371 )
Net cash provided by (used in) investing activities     (26,576 )     1,735,126  
                 
Cash flows from financing activities                
Cash raised by sale of class “D” preferred stock     2,750,000        
Cash paid for dividend     (150,831 )      
Cash raised through issuance of debt     965,140       410,000  
Repayment of debt     (410,000 )      
Investor deposit     (210,100 )      
Net cash used in financing activities     2,944,209       410,000  
Effects of currency translation on cash and cash equivalents     1,887        
Net increase/(decrease) in cash and cash equivalents     (223,368 )     449,635  
Cash and cash equivalents - beginning of period     1,770,729       197,231  
Cash and cash equivalents - end of period   $ 1,547,361     $ 646,866  
                 
Supplemental cash flow disclosures                
Cash paid for interest   $ 42,217     $  
Cash paid for income taxes   $ 9,878     $  
Cash paid for China representative office tax   $ 13,950     $  

 

Supplemental disclosure of non-cash activity

 

During the three and six months ended November 30, 2017, the company received various stocks valued (FMV) at $422,200 and $1,006,575, respectively, for providing one to twelve months of investor relations (“IR”) services.

 

During the three and six months ended November 30, 2016, the company received various stock valued (FMV) at $134,000 and $280,000, respectively, for providing one to twelve months of investor relations (“IR”) services.

 

 

See accompanying notes to the financial statements

 

  5  
 


NOTES TO THE FINANCIAL STATEMENTS

(UNAUDITED)

 

Organization and Nature of Operations :

 

Business Description

 

Chineseinvestors.com , Inc. (the “Company”) was incorporated on June 15, 1999 in the State of California. The Company is a provider of Chinese language web-based real-time financial information. The Company’s operations had been located in California until September 2002 at which time the operations were relocated to Shanghai, in the People’s Republic of China (PRC). The Company relocated part of the operations in California starting fiscal year 2017.

 

During May 2000, the Company entered into an agreement with MAS Financial Corp. (“MASF”) whereby MASF agreed to transfer control of a public shell corporation to the Company and perform certain consulting services for a fee of $30,000.

 

During June 2000, the Company completed reorganization with MAS Acquisition LII Corp. (“MASA”) with no operations or significant assets. Pursuant to the terms of the agreement, the Company acquired approximately 96% of the issued and outstanding common shares of MASA in exchange for all of its issued and outstanding common stock. MASA issued 8,200,000 shares of its restricted common stock for all of the issued and outstanding common shares of the Company. This reorganization was accounted for as though it were a recapitalization of the Company and sale by the Company of 319,900 shares of common stock in exchange for the net assets of MASA. In conjunction with the reorganization MASA changed its name to Chineseinvestors.com, Inc.

 

The Company is now incorporated as a C corporation in the State of Indiana as of June 1, 1997.

 

In March 2017, the Company established and registered XiBiDi Biotechnology Co., Ltd. (“CBD Biotechnology Co., Ltd”) in the Pudong Free-Trade Area in Shanghai, established as a wholly owned foreign enterprise. In April, CIIX appointed XiangYang Yun as chief executive officer (CEO) of this wholly owned foreign enterprise. XiBiDi Biotechnology Co. Ltd.’s primary focus is online, retail and direct sales of hemp-based health products in China. Yun’s initial focus was the launch of the XiBiDi Magic Hemp Series (“CBD Magic Hemp Series”), a cosmetics line which included three initial products, namely, the CBDBIO TECH Brightening and Refreshing Moisturizer, the CBDBIO TECH Perfecting Shield Primer, and the CBDBIO TECH Peptide Collagen Solution.

 

In November 2017, CBD Biotechnology Co. Ltd., teamed up with Chinese beauty influencer, The Godfather of Beauty , for the launch of its “CBD Magic Hemp Series” skincare line on China’s largest e-commerce retailer Alibaba. The Company’s flagship store, the "CBD Enterprise Store," is on Alibaba’s Taobao Platform. The Godfather of Beauty is an Internet celebrity with years of experience in live, online marketing on the Taobao Platform.

 

In November 2017, CBD Biotechnology Co. Ltd. also announced the expansion of its consumer division to enter the lucrative liquor (baijiu) market in China. On November 7, 2017, CBD Biotechnology was issued Wholesale Alcohol License from the ShangHai Wine Monopoly Bureau effective October 24, 2107 for a three year term, which allows CBD Biotechnology to act as a distributor of the baijau. CBD Biotechnology entered into a wholesale agreement with China GuiZhou HanTai Wine, Inc. to distribute its baijui, Yantai 1985, and kicked off its sales and marketing plan by partnering with Jinri Toutiao (translation: Today’s Headlines), a popular Chinese mobile application. The Company announced plans to spin off CBD Biotechnology Co. Ltd. at the end of February 2018; however, the Company’s Board of Directors has recently approved postponing the spin-off until the Company’s fiscal year end May 31, 2018.

 

In April 2017, the Company established ChineseHempOil.com, Inc. dba “Chinese Wellness Center” a Delaware corporation, as a subsidiary of the Company. ChineseHempOil.com, Inc. is responsible for the development and operation of the online and retail sales of non-industrial hemp-based health products in the United States. Chinese Wellness Center is the retail store located in the predominantly Chinese community of San Gabriel, California, located next to the Company’s headquarters. In addition, ChineseInvestors.com, Inc. announced the release of its first hemp oil product line, OptHemp, a premium, private label oil, made from full-spectrum, Colorado grown, GMO-Free, non-industrial hemp, manufactured using a CO 2 Extraction process.

 

In November 2017, ChineseHempOil.com, Inc. launched its OptHemp product line on Amazon.com kicking off a multi-channel campaign geared to both the US and Chinese-American markets during the 9th annual Singles Day Celebration. This launch commenced the e-commerce marketplace initiative that the Company set into motion in early June through a strategic partnership with a top 100 platinum level partner seller on Amazon Marketplace that agreed to include the OptHemp product line in its limited catalog for resale through the Amazon Channel. This partnership brings to the OptHemp product line the full weight and power of a national sales and marketing agency that specializes in providing business solutions including headquarter sales services, analytics, insights and intelligence, retail services, marketing, digital technology and business process outsourcing. The Company announced plans to spin off ChineseHempOil.com, Inc at the end of February 2018; however, the Company’s Board of Directors has recently approved postponing the spin-off until the Company’s fiscal year end May 31, 2018.

 

In an effort to expand its media products, as the first quarter of fiscal year 2018 came to a close, the Company announced that it would be working with Wall Street Multimedia (“WSM”), an independent news agency located in the NYSE to produce a daily cryptocurrency video newscast in Chinese, providing timely information and exclusive analysis regarding all aspects of the emerging digital currency world, including specific cryptocurrencies, such as “Bitcoin” and “Ethereum,” industry trends, price movement, blockchain technology, sector-related stocks and ETFs, etc.

 

 

 

  6  
 

 

1. Liquidity and Capital Resources:

 

Cash Flows – During the six months ended November 30, 2017, the Company primarily generated cash and cash equivalents, from issuances of its common and preferred stock to fund its operations. The Company received $2,750,000 of proceeds from the sale of Series “D-2017” preferred stock by November 30, 2017. Except $100,000 was received in the year ended May 31, 2017, the remaining was received during the six months ended November 30, 2017. 

 

Cash flows provided by (used in) operations for the six months ended November 30, 2017 and 2016 were $(3,142,888) and $(1,695,491), respectively. The increased cash used in operations were due to increased general and administrative expenses used in operation.

 

Capital Resources – As of November 30, 2017, the Company had cash and cash equivalents of $1,547,361 as compared to cash and cash equivalents of $1,770,729 as of May 31, 2017.

 

Since inception in 1997, the Company has primarily relied upon proceeds from private placements of its equity securities to fund its operations. The Company anticipates continuing to rely on sales of our securities in order to continue to fund business operations. Issuances of additional shares will result in dilution to its existing stockholders. There is no assurance that the Company will be able to complete any additional sales of our equity securities or that it will be able arrange for other financing to fund our planned business activities.

 

Going Concern  – The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is potential that the Company will not continue as a going concern. The recoverability of recorded property and equipment, intangible assets, and other asset amounts shown in the accompanying financial statements is dependent upon the Company’s ability to continue as a going concern and to achieve a level of profitability. The Company intends on financing its future activities and its working capital needs largely from the sale of equity securities until such time that funds provided by operations are sufficient to fund working capital requirements. However, there can be no assurance that the Company will be successful in its efforts. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

2. Critical Accounting Policies and Estimates :

 

Basis of Presentation – These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial statements.

 

Principles of Consolidation  - The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America.

 

The consolidated financial statements include the accounts of Chineseinvestors.com Inc and its subsidiaries (collectively the “Company”). The Company’s subsidiaries include 100% of ChineseHempOil.com Inc, XiBiDi Biotechnology Co, Ltd, Hemp Logic and CIIX Online.

 

Intercompany accounts and transactions have been eliminated upon consolidation.

 

Foreign Currency – The Company has operations in the People’s Republic of China (“PRC”), however the functional and reporting currency is in U.S. dollars. To come to this conclusion, the Company considered the direction of ASC section 830-10-55.

 

Selling Price and Market – As a representative office is located in the PRC, the Company is not allowed to sell directly to PRC based customers. Over 90% of its customers are in the United States and 100% of all sales are paid in U.S. dollars. This indicates the functional currency is U.S. dollars.

 

Financing – The Company’s financing has been generated exclusively in U.S. dollars from the United States. This indicates the functional currency is U.S. dollars.

 

Expenses – The majority of expense are paid in U.S. dollars. The expenses generated in PRC are paid by a monthly or weekly cash transfer from the U.S. when the expenses are due, resulting in very little foreign currency exposure. This indicates the functional currency is U.S. dollars.

 

 

 

 

  7  
 

 

Numerous Intercompany Transactions – The Company has multiple transactions each month between the U.S. and Chinese representative office. This indicates the functional currency is U.S. dollars.

 

Beside the above, one subsidiary XiBiDi Biotechnology Co Ltd's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Owners’ contribution is translated at historical rate. Income and expenditures are translated at the average exchange rate of the period. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.

 

XiBiDi Biotechnology Co Ltd was not established until March 2017, therefore there is no translation for statement of comprehensive (loss) and income for three-month period end November 30, 2016 and six-month period end November 30, 2016. The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:

 

November 30, 2017  
Balance sheet RMB 6.60 to US $1.00
Statement of comprehensive (loss) and income-three-month period RMB 6.62 to US $1.00
Statement of comprehensive (loss) and income-six-month period RMB 6.67 to US $1.00
May 31, 2017  
Balance sheet RMB 6.80 to US $1.00

 

Revenue recognition  — Revenue was derived from five different sources:

 

The Company recognizes revenue pursuant to revenue recognition principles presented in SAB Topic 13. First, persuasive evidence of an arrangement. Second, deliver has occurred or services have been rendered, thirdly the seller’s price to the buyer is fixed or determinable and lastly collectability is reasonably assured.

  

1. Fees from banner advertisement, webpage hosting and maintenance, on-line promotion and translation services, advertising and promotion fees for customers in the Company’s Chinese Investment Guides, sponsorship fees from investment seminars, road shows, and forums. The sales prices of these services are fixed and determinable at the time the contracts are signed and there are no provisions for refunds contained in the contracts. These revenues are recognized when all significant contractual obligations have been satisfied and collection of the resulting receivable is reasonably assured.

 

2. Fees from membership subscriptions: these revenues are recognized over the term of the subscription. Subscription terms are generally between 3 and 12 months but can occasionally be as short as 1 month or as long as 60 months. Long term deferred revenues are recognized from subscriptions over 12 months.

 

3. Fees related to setting up and providing ongoing administrative and translation support for currency trading accounts are in association with Forex. These fees are recognized when earned.

 

4. Investor relations income is earned by the Company in return for delivering current, publicly available information related to our client companies. These revenues are prepaid by the client company and as such are initially recorded as an asset with an offsetting unearned revenue liability. This revenue is recognized over the term of the services period while the services are being provided. The value of the revenue earned is recognized every quarter based upon fair market value of the client company’s stock closing price at contract date multiplied by the numbers of shares earned. By recognizing the revenue incrementally, we are following the guidelines of SAB Topic 13, in that we are only recognizing revenue once the value of the revenue received is fixed and determinable. In addition, we are applying the definition of readily determinable fair value presented at Accounting Standards Codification 820-10-15-5 in assessing the amount to recognize in each accounting period. The revenue is recognized over the term of the service period.

 

5. The Company recognizes revenue for product sales upon transfer of title to the customer. Customer purchase orders and/or contracts are generally used to determine the existence of an arrangement. Shipping documents and terms and the completion of any customer acceptance requirements, when applicable, are used to verify product delivery. The Company assesses whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. The Company has no product returns or sales discounts and allowances because goods delivered and accepted by customers are normally not returnable.

 

 

 

  8  
 

 

Costs of Services/Products Sold  – Costs of services provided are the total direct cost of the Company’s operations in Shanghai. Cost of goods sold includes cost of inventory sold during the period, net of discounts and inventory allowances, freight and shipping costs, warranty and rework costs.

 

Website Development Costs – The Company accounts for its Development Costs in accordance with ASC 350-50, “Accounting for Website Development Costs.” The Company’s website comprises multiple features and offerings that are currently developed with ongoing refinements. In connection with the development of its products, the Company has incurred external costs for hardware, software, and consulting services, and internal costs for payroll and related expenses of its technology employees directly involved in the development. All hardware costs are capitalized as fixed assets. Purchased software costs are capitalized in accordance with ASC codification 350-50-25 related to accounting for the costs of computer software developed or obtained for internal use. All other costs are reviewed to determine whether they should be capitalized or expensed.

 

Cash and Cash Equivalents – The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. At certain times, cash in bank may exceed the amount covered by FDIC insurance. At November 30, 2017 and May 31, 2017 there were deposit balances in a United States bank of $1,413,341 and $1,716,138 respectively. In addition, the Company maintains cash balance in The Bank of China, which is a government owned bank. The full balance of the deposits in China is secured by the Chinese government.

 

Accounts Receivable and Concentration of Credit Risk – The Company extends unsecured credit to its customers in the ordinary course of business. Accounts receivable related to subscription revenue is recorded at the time the credit card transaction is completed, and is completed when the merchant bank deposits the cash to the Company bank account. Revenues related to advertising and Forex are regularly collected within 30 days of the time of services being rendered. However, since these are ongoing contracts, there has been no instance of failure to pay.

 

The Company evaluates the need for an allowance for doubtful accounts on a regular basis. As of November 30, 2017 and May 31, 2017, the Company determined that an allowance was not needed.

 

The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy.

 

Investments, available for sale, in affiliate  – The Company invested in an affiliate, Medicine Man Technologies, Inc. (“MDCL”), in April 2014, implemented the equity method of accounting. The Company received its ownership in return for supporting the company during its formational stage and no cash, as such the stock received had a value of zero and the affiliate generated a loss through May 31, 2014. The Company has no further commitment to fund losses; therefore, management has deemed it proper to discontinue applying the equity method for the investment as defined by Accounting Standards Codification (“ASC”) 323-10-35-20 for the year ended May 31, 2014. In 2015 the affiliate company issued additional stock, diluting the Company’s position and restructured the management of the entity causing the Company to determine that it no longer had “significant influence” over its operations. The Company then started accounting for the stock owned as an available for sale security. As there was a public market for MDCL stock at November 30, 2017 and May 31, 2017, the Company recognized the stock as a Level 1 financial instrument. The Company has liquidated most of its holdings in MDCL stock generating approximately $0 and $1,896,939 cash during the six months period ended November 30, 2017 and 2016, respectively. At November 30, 2017, the Company still held 41,238 shares of MDCL stock representing $69,691 of value based upon the closing market price of $1.69. At May 31, 2017, the Company held 41,238 shares of MDCL stock representing $72,166 of value based upon the closing market price of $1.75.

 

Investments available for sale Investments available for sale is comprised of publicly traded stock received in return for providing investor relations services to client companies. The investor relations services range from one month to a year, from the inception of the contract. The Company considers the securities to be liquid and convertible to cash in under a year. The Company has the ability and intent to liquidate any security that the Company holds to fund operations over the next twelve months, if necessary, and as such has classified all of its marketable securities as short-term.

 

The Company followed the guidance of ASC 320-10-30 to determine the initial measure of value based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction, in accordance with the provisions of topic 820-10-15-5, which states that an equity security has a readily determinable fair value if it meets the condition of having a “sales prices or bid-and-asked quotations which are currently available on a securities exchange registered with the U.S. Securities and Exchange Commission (SEC) or in the over-the-counter market, provided that those prices or quotations for the over-the-counter market are publicly reported by the National Association of Securities Dealers Automated Quotation systems or by the OTC Markets Group Ins. Restricted stock meets that definition if the restriction terminates within one year.” These shares were classified as available for sale securities in accordance with ASC 948-310-40-1 as the Companies intention is to sell them in the near-term (less than one year). In compliance with ASC 320-10-35-1, equity securities that have readily determinable fair values that are classified as available-for-sale shall be measured subsequently at fair value in the statement of financial position. Unrealized holding gains and losses for Available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized.

 

 

 

 

  9  
 

 

As these shares will be earned over the term of the contracts, the Company will defer the recognition of the earnings of the revenue over the period the services are performed. The value recorded will be determined by multiplying the average of the closing price on the last day of the month for the period being reported based on closing market price per share.

 

Upon receipt, these shares were recorded as an asset on the Companies financials as "Investments, available for sale". The Company will also record a corresponding contra-asset account titled "Unearned Revenue paid in stock".

 

Inventories  – Inventory is valued at the lower of cost or net realizable value. Cost is determined using weighted average cost method. There is no write-off as of November 30, 2017 and May 31, 2017.

 

Other Current Assets – Other current assets consist of deposits in Chinese Renminbi on building space under an operating lease and are stated at the current exchange rate at year end. Security deposits of office rent in United States, purchase deposits to vendors for the Hemp oil purchase, prepaid expenses in both United States and Shanghai, details as below:

 

    November 30,     May 31,  
    2017     2017  
Purchase deposit   $     $ 66,125  
Prepaid expense     138,605       151,238  
Security deposit-rent     40,536       43,909  
Other current assets     125,361       10,084  
    $ 304,502     $ 271,401  

 

Investment-affiliate – The Company made investment of $250,000 to Breakwater MB LLC in March 2017, a cannabis-focused investment and consulting company, formed by the Company’s board member and CFO, Paul Dickman, as a means to invest capital in and provide consulting services to private, cannabis-focused companies as they transition into the public market. The Company’s equity position in Breakwater MB, LLC will be approximately 12.5%. The Company adopt cost method for this investment.

 

Property and Equipment – Property and equipment are stated at cost. Depreciation and amortization of property and equipment is provided using the straight-line method over estimated useful lives ranging from three to five years. Leasehold improvements are amortized over the life of the lease. Depreciation and amortization expense was $12,947 and $6,855 for the six months ended November 30, 2017 and 2016, respectively.

 

Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. Gains and losses from retirement or replacement are included in operations.

 

Impairment of Long-life Assets – In accordance with ASC Topic 360, the Company reviews its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There was no impairment for the periods ended November 30, 2017 and 2016 .

 

Accrued dividend & interest – The accrued dividend balance represents dividend payable related to the Series A-2014 preferred stock Series C-2016 preferred stock and Series D-2017 preferred stock. Accrued dividend was $155,539 and $150,831 for the period ended November 30, 2017 and May 31, 2017 respectively. The accrued interest balance represents interest payable for short term debt outstanding. Accrued interest was $2,950 and $16,857 for the period ended November 30, 2017 and May 31, 2017 respectively.

 

Accrued Liabilities – Accrued liabilities are comprised of the following:

 

    November 30, 2017     May 31, 2017  
China Employees' Salaries and Commissions Accrual   $ 6,799     $ 6,799  
Other Accruals     126,780       60,983  
    $ 133,579     $ 67,782  

 

Unearned revenue, revenue paid in stock – For the six months ended November 30, 2017 and during fiscal year ended May 31, 2017, the Company received shares of stock and warrants, as payment for investor relations work that the Company will be providing through July 2018. As the Company earns the fee for this work, this balance will be reduced to reflect the portion still to be earned.

 

 

 

  10  
 

 

Deferred revenue – The Company receives payment for subscription revenues in advance before the subscription service is granted. The company recognizes the revenue as being earned as the services are deliver. The amount paid for which services have not yet been delivered related to subscription revenues is recorded as a liability in the current or long-term portion of the liabilities section of the balance sheet. 

 

Short-term debt, secured by stock

 

In September 2016, the Company obtained short-term debt of $410,000 from various individuals. Based on the original lending agreements, the loan was to have been secured by shares of the stocks in the following companies. 

 

Company name Shares Secured for Loan
Sino-Global Shipping America LTD (SINO) 80,000.00
Recon Technology LTD (RCON) 60,000.00
Nengfa Weiye Energy (NFEC) 185,000.00
SGOCO Group LTD (SGOC) 28,333.33

 

When entering the loan agreement, the Company believed that the contract would be executed and SINO shares would be delivered upon signing the contract. However, such IR service agreement was not executed due to a disagreement among SINO’s management, as a result, the Company did not obtain the SINO shares as of November 30, 2017. For NFEC, the Company obtained 100,000 shares at the time of entering the contract, and the remaining shares were fully received by the end of year 2016. For RCON, the Company obtained 50,000 shares at the time entering the contract, but the agreement called for collateral of 60,000 RCON shares, the collateral is now short by 10,000 shares of RCON common stock. The loan agreements are still valid after renegotiating the terms with the private lenders. These notes are due on September 2017. The lenders received a 20% of the deemed increase in value of these secured shares (“Incentive Feature”) at the maturity of the short-term note.

 

It has been determined that these notes were not properly collateralized as the ownership of the collateral did not transfer from the Company to the collateral agent. All notes that were not properly collateralized have been repaid or renegotiated into new notes, which themselves have not been collateralized. The Company paid back principal and interest to borrowers for a total of $343,051. The reminder of the principal and interest represented by the notes were rolled over to new notes with an outstanding principle balance totaling $116,669.

 

In November 2017, the Company obtained short-term debt of $965,140 from various individuals. Of the $965,140, $116,669 was rolled over from previous debt. The loans were to be secured by shares of the stocks in the following companies:

 

Company name Shares Secured for Loan
Nemaura Medical, Inc (NMRD) 104,000.00
Recon Technology LTD (RCON) 49,999.00
Solbright Group Inc. (SBRT) 195,122.00
Nengfa Weiye Energy (NFEC) 170,702.00
SGOCO Group LTD (SGOC) 29,412.00

 

The new notes have not been secured by the pledge of those securities.

 

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation and useful lives, and contingencies. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.

 

Fair Value of Financial Instruments – The Company has adopted the provisions of ASC Topic 820, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

 

  Level one – Quoted market prices in active markets for identical assets or liabilities;

 

  Level two – Inputs other than level one inputs that are either directly or indirectly observable; and

 

  Level three – Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

 

 

 

  11  
 

 

Much of the Company’s financial instruments are level one and are carried at market value, requiring no adjustment to book value. The financial instruments classified as level one were deemed to qualify as that classification because their value was determined by the price of identical instruments traded on an active exchange.

 

Level one instruments are based upon stated balance of financial institution or calculated based upon stock trading in the public market. Level two instruments are calculated based upon the sale of stock through a private placement at arms-length where our shares were an insignificant amount of the total volume of stock sold in the issuer. Level three financial instruments were valued by a professional independent appraiser hired by the Company to determine the valuation. The level three valuation calculation includes discounted cash flow models and market based models as appropriately utilized by a professional valuation firm. The inputs they used included the entities past financial performance, projected budgets, prior private stock sale history and comparable company valuations.

 

The following table summarizes the assets we are carrying and the fair value category in which they are currently classified:

 

    November 30, 2017     May 31, 2017  
    Level 1     Level 2     Level 3     Level 1     Level 2     Level 3  
Cash     1,547,361                   1,770,729              
Investments     1,418,382       250,000             729,075       250,000        
Total Financial Instruments     2,965,743       250,000             2,499,804       250,000        

 

Income Taxes – Income taxes are accounted for under the asset and liability method of ASC 740. Deferred tax assets and liabilities are recognized for net operating loss and other credit carry forwards and the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the tax effect of transactions are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the year that includes the enactment date.

 

Deferred tax assets are reduced by a full valuation allowance since it is more likely than not that the amount will not be realized. Deferred tax assets and liabilities are classified as current or noncurrent based on the classification of the underlying asset or liability giving rise to the temporary difference or the expected date of utilization of the carry forwards.

 

Other Revenue – Other revenue is comprised of revenue related to Forex service fees, rent generated through office space sublease revenue and other miscellaneous service revenues generated which is recognized over the period the term of the lease for the period ended November 30, 2017 and 2016.

 

Advertising Costs – Advertising costs are expensed when incurred.

 

Earnings (Loss) Per Share – Earnings (loss) per share is computed using the weighted average number of common shares outstanding during the period. The Company has adopted ASC 260 “Earnings Per Share”. Fully diluted loss per share are not calculated and presented on the financial statements as the calculation would be antidilutive.

 

Stock Based Compensation – The Company accounts for share-based payments pursuant to ASC 718, “Stock Compensation” and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options and restricted stock awards using the Black-Scholes option pricing model.

 

Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and EITF 96-18 when stock or options are awarded for previous or current service without further recourse. The Company issued stock options to contractors and external companies that had been providing services to the Company upon their termination of services. Under ASC 718 and EITF 96-18 these options were recognized as expense in the period issued because they were given as a form of payment for services already rendered with no recourse.

 

On July 14, 2017, the Company awarded and issued a restricted stock award to a service provider 30,000 shares in total, and the fair market value at the grant date was $0.80 per share. All these shares were fully vested at grant date, stock compensation expense totaling $24,120 were recorded.

 

On August 7, 2017, the Company awarded and issued a restricted stock award to a service provider 50,000 shares in total, and the fair market value at the grant date was $0.87 per share. All these shares were fully vested at grant date, stock compensation expense totaling $43,500 were recorded.

 

On October 31, 2017, the Company awarded restricted stock awards to various employees 1,340,000 shares in total, and the fair market value at the grant date was $0.49 per share. All these shares were fully vested at grant date, stock compensation expense totaling $656,600 were recorded.

 

 

 

  12  
 

  

Preferred Stock Beneficial Convertible Feature Upon issuance of preferred stock convertible into shares of common stock at a price lower than the fair market value of common stock on the date of issuance, in accordance with the guidance provided in ASC 505-10-50 and Emerging Issues Task Force (“EITF”) No. 00-27, we have recorded the intrinsic value of this beneficial conversion feature(“BCF”) .

 

In according to ASC 470-20-30-6 Intrinsic value shall be calculated at the commitment date as the differences between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. In according to ASC 470-20-30-8, if the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the beneficial conversion feature shall be limited to the amount of the proceeds allocated to the convertible instrument. Since all the preferred stocks are issued on different date, we calculate the intrinsic value for each individual preferred stock issuance based on stock issuance date. If the intrinsic value exceeds actual proceeds we received, actual proceeds will be BCF, otherwise the intrinsic value is the BCF.

 

New Accounting Pronouncements – Upon issuance of final pronouncements, we review the new accounting literature to determine its relevance, if any, to our business. The Company is in the progress of evaluating the following accounting updates:

 

In May 2017, the FASB issued ASU NO. 2017-09 Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, Effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance.

 

In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”. The amendments add further guidance on identifying performance obligations and also to improve the operability and understandability of the licensing implementation guidance. The amendments do not change the core principle of the guidance in Topic 606. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements in Topic 606. The Company is currently in the process of evaluating the impact of the adoption on its consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”. The amendments, among other things: (1) clarify the objective of the collectability criterion for applying paragraph 606-10-25-7; (2) permit an entity to exclude amounts collected from customers for all sales (and other similar) taxes from the transaction price; (3) specify that the measurement date for noncash consideration is contract inception; (4) provide a practical expedient that permits an entity to reflect the aggregate effect of all modifications that occur before the beginning of the earliest period presented when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations; (5) clarify that a completed contract for purposes of transition is a contract for which all (or substantially all) of the revenue was recognized under legacy GAAP before the date of initial application, and (6) clarify that an entity that retrospectively applies the guidance in Topic 606 to each prior reporting period is not required to disclose the effect of the accounting change for the period of adoption. The effective date of these amendments is at the same date that Topic 606 is effective. The Company is currently in the process of evaluating the impact of the adoption on its consolidated financial statements. In December 2016, the FASB issued ASU 2016-20,  “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers”.  The amendments in ASU 2016-20 affect narrow aspects of the guidance issued in ASU 2014-09 including Loan Guarantee Fees, Contract Costs, Provisions for Losses on Construction-Type and Production-Type Contracts, Disclosure of Remaining Performance Obligations, Disclosure of Prior Period Performance Obligations, Contract Modifications, Contract Asset vs. Receivable, Refund Liabilities, Advertising Costs, Fixed Odds Wagering Contracts in the Casino Industry, and Costs Capitalized for Advisors to Private Funds and Public Funds. The effective date of these amendments are at the same date that Topic 606 is effective. Topic 606 is effective for public entities for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein (i.e., January 1, 2018, for a calendar year entity). The Company is currently in the process of evaluating the impact of the adoption on its consolidated financial statements.

 

The Company has considered all new accounting pronouncements and has concluded that there are no new pronouncements that may have a material impact on results of operations, financial condition, or cash flows, based on current information.

 

  13  
 

  

3. Stockholders’ Equity:

 

As of November 30, 2017 and May 31, 2017, the Company was authorized to issue 80,000,000 shares of common stock, $0.001 par value per share. In addition, 20,000,000 shares of $.001 par value preferred stock were authorized. All common stock shares have full dividend rights. However, it is not anticipated that the Company will be declaring distributions in the foreseeable future.

 

During the year ended May 31, 2016, the Company bought back 62,500 shares of company stock from former COO Brett Roper, but those shares has not been returned as of November 30, 2017. The Company has communicated with Mr. Brett Roper, confirmed shares will be returned soon and recorded with transfer agent.

 

During the six months period ended November 30, 2017, the shareholders of preferred stock series 2012 converted 150,000 shares of preferred stock for 187,500 of common stock shares at a conversion rate of 1 share of preferred stock series 2012 for 1.25 shares of common stock.

 

During the six months period ended November 30, 2017 the shareholders of preferred stock series A-2014 converted 994,000 shares of preferred stock for 2,485,000 of common stock shares at a conversion rate of 1 share of preferred stock series A-2014 for 2.50 shares of common stock.

 

During the six months period ended November 30, 2017, the shareholders of preferred stock series C-2016 converted 2,908,085 shares of preferred stock for 8,724,255 of common stock shares at a conversion rate of 1 share of preferred stock series C-2016 for 3.00 shares of common stock.

 

During the six months period ended November 30, 2017, the company received $2,750,000 proceeds from the sale of preferred stock series D-2017.

 

During the six months period ended November 30, 2017, the Company granted and issued 1,420,000 shares of restricted common stock for compensation. Of the 1,420,000 shares, 1,340,000 were not distributed and recorded as stock compensation payable on balance sheet. The stock was valued from $0.49 to $0.87 per share based on the market price at the grant date. The compensation and consulting expense was recorded as general and administrative expenses for the period ended November 30, 2017.

 

Series 2012 Convertible Preferred Stock

 

During the third quarter of fiscal year 2013, effective February 29, 2012, the Company issued 2,003,776 shares of preferred stock as Series 2012 convertible preferred stock for total proceeds of $2,003,776. The terms of the preferred stock allow the holder to convert each share of preferred stock into 1.25 shares of common stock at any time after nine months from the date of issuance. The holders of shares of preferred stock were entitled to receive a dividend of $0.06 per share per annum for the first two years from the issuance of the instruments. The Company maintained the right to suspend the dividend at its discretion if it is deemed necessary.

  

Series A-2014 Convertible Preferred Stock

 

In the years ended May 31, 2016 and 2015 the Company issued 720,000 and 1,885,000 shares of preferred stock as Series A-2014 convertible preferred stock for total proceeds of $2,605,000. The terms of the preferred stock allow the holder to convert each share of preferred stock into 2.5 shares of common stock at any time after six months from the date of issuance. The holders of shares of preferred stock shall have the right to one vote for each share of common stock into which such preferred stock could convert. The holders of shares of preferred stock are entitled to receive a dividend of $0.06 per share per annum for the first two years from the issuance of the instruments, which has been recorded as an accrued dividend on the liabilities section of the balance sheet. The Company maintained the right to suspend the dividend at its discretion if it is deemed necessary.

 

Series C-2016 Convertible Preferred Stock

 

In December 2016, the Company issued 5,000,043 shares of its Series C-2016 Preferred Stock at a price of $1.00 per share for total proceeds of $5,000,043. The terms of the preferred stock allow the holder to convert each share of preferred stock into 3 shares of common stock at any time after six months from the date of issuance. The holders of shares of preferred stock are entitled to receive a dividend of $0.06 per share per annum for the first year from the issuance of the instruments, which has been recorded as an accrued dividend on the liabilities section of the balance sheet. The Company maintained the right to suspend the dividend at its discretion if it is deemed necessary.

 

 

 

 

  14  
 

 

We calculated the BCF of the Series C-2016 stock as $4,930,143. The BCF would be recorded as paid-in capital with an offsetting debit to convertible preferred stock. The discount attributable to the BCF, however, is amortized as a deemed dividend over the period from issuance to the date the convertible preferred stock becomes convertible. In our case, preferred stock-series C-2016 is convertible after six months from the date of issuance. We then amortize the BCF over six months period, we recorded $3,685,520 as deemed dividend that reduce accumulated deficit as of May 31, 2017, and we recorded the remaining $1,244,622 as deemed dividend that increases accumulated deficit for the period ending August 31, 2017.

 

Series D-2017 Convertible Preferred Stock

 

In October 2017, the Company issued 2,750,000 shares of its Series D-2017 Preferred Stock at a price of $1.00 per share for total proceeds of $2,750,000. The terms of the preferred stock allow the holder to convert each share of preferred stock into 2 shares of common stock at any time from the date of issuance. The holders of shares of preferred stock are entitled to receive a dividend of $0.06 per share per annum for the first two years from the issuance of the instruments, which has been recorded as an accrued dividend on the liabilities section of the balance sheet. The Company maintained the right to suspend the dividend at its discretion if it is deemed necessary.

 

We calculated the BCF of the preferred shares as $1,803,720. The BCF would be recorded as paid-in capital with an offsetting debit to convertible preferred stock. The discount attributable to the BCF, however, is amortized as a deemed dividend over the period from issuance to the date the convertible preferred stock becomes convertible. In our case, preferred stock-series D-2017 is convertible from the date of issuance. We then amortize the BCF over six months period, we recorded $1,803,720 as deemed dividend that increases accumulated deficit as of November 30, 2017.

 

4. Property and Equipment :

 

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

 

    November 30, 2017     May 31, 2017  
Furniture & Fixtures   $ 127,763     $ 126,486  
Leasehold Improvements     32,061       32,061  
    $ 159,824     $ 158,547  
Less: Accumulated Depreciation     (113,310 )     (105,515 )
    $ 46,514     $ 53,032  

 

Depreciation on equipment is provided on a straight-line basis over their expected useful lives at the following annual rates.

 

Computer equipment   3 years
Furniture & fixtures   3 years
Leasehold improvements   Term of the lease

 

Depreciation expense for the six months ending November 30, 2017 and 2016 was $7,795 and $1,901, respectively.

 

5. Intangible Assets :

 

Intangible assets are comprised of the following:

 

    November 30, 2017     May 31, 2017  
Website development   $ 212,842     $ 187,544  
Less: Accumulated Amortization     (111,009 )     (105,857 )
    $ 101,833     $ 81,687  

 

Amortization is calculated over a straight-line basis using the economic life of the asset. Amortization expense for the six months ended November 30, 2017 and 2016 was $5,152 and $4,954 respectively.

 

 

 

 

  15  
 

 

6. Commitments and Concentrations:

  

Office Lease – Shanghai – The Company entered into a lease for new office space in Shanghai, China. The lease period started October 1, 2013 and the initial term ended on September 30, 2016. In August 2016, the Company renewed this lease at $5,400 per month to September 30, 2019, resulting in the following future commitments:

 

2018 fiscal year   $ 32,400  
2019 fiscal year   $ 64,800  
2020 fiscal year   $ 21,600  

        

Office Lease – San Gabriel, California – The Company entered a lease for executive office space in San Gabriel, California. The Lease period started April 30, 2015 and was terminated on August 1, 2016. On June 2016, the Company renewed the contract for another 3 years to July 31, 2019, the current monthly rent is $5,432, resulting in the following future commitments:

 

2018 fiscal year   $ 33,532  
2019 fiscal year   $ 67,064  
2020 fiscal year   $ 11,177  

 

The Company entered another lease for retail store in San Gabriel, California. The lease period started February 1, 2017 to July 31, 2019, the current monthly rent is $3,243, resulting in the following future commitments:

 

2018 fiscal year   $ 19,462  
2019 fiscal year   $ 38,924  
2020 fiscal year   $ 6,487  

 

Concentrations – During the periods ending November 30, 2017 and 2016, the majority of the Company’s revenue was derived from its operations in PRC from individual subscribers, primarily in the United States and Canada.

 

Litigation – The Company is involved in legal proceedings from time to time in the ordinary course of its business. As of the date of this filing, the Company is not involved in any legal proceedings.

 

7. Subsequent event :

 

The Company is currently in the process of offering up to 10,000,000 shares at $1 per share total $10,000,000 of its Series D-2017 Convertible Preferred Stock. Each share of Series D-2017 Preferred Stock is convertible into 2 shares of the Company’s common stock. The Series D-2017 Convertible Preferred Stock will pay at least two years of dividends at the rate of 6% per year on the original investment of $1 per share of Series D-2017 Convertible Preferred Stock. As of the filing date, the Company received $5,358,050 proceeds from sales of Series D-2017 convertible preferred stock, $2,605,000 of these preferred stock has been recorded with stock-transfer agent as of November 30,2017, the rest are in the process of recording with the transfer agent.  

 

 

 

 

 

 

 

 

 

 

  16  
 


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

ChineseInvestors.com, Inc and subsidiaries . (“the Company”, “we” or “us”) endeavors to be an innovative company, specializing in (a) providing real-time market commentary, analysis, and educational related endeavors in Chinese language character sets (traditional and simplified), (b) providing support services to our various partners wishing to have a Chinese language communications component, (c) providing consultative services to smaller private companies considering becoming a public company, (d) providing various advertising as well as public relation support services, and (e) other services we may identify having the potential to create value or partnership opportunity with our existing services.

 

During the first quarter of fiscal year 2017 the company continued to develop its investor relations business. These clients represent companies whose shares are traded in various public markets including the OTCBB, NASDAQ, and NYSE exchanges.

 

In an effort to expand its media products, as the first quarter of fiscal year 2018 came to a close, the Company announced that it would be working with Wall Street Multimedia (“WSM”), an independent news agency located in the NYSE to product a daily cryptocurrency video newscast in Chinese, providing timely information and exclusive analysis regarding all aspects of the emerging digital currency world, including specific cryptocurrencies, such as “Bitcoin” and “Ethereum,” industry trends, price movement, blockchain technology, sector-related stocks and ETFs, etc. As of the date of this filing the Company has begun airing its cryptocurrency video newscasts.

 

XiBiDi Biotechnology Co., Ltd .

 

In March 2017, the Company established and registered XiBiDi Biotechnology Co., Ltd. (“CBD Biotechnology Co., Ltd”) in the Pudong Free-Trade Area in Shanghai, established as a wholly owned foreign enterprise. The Chinese character “XiBiDi” is homophonic to “CBD” in English.In April, CIIX appointed XiangYang Yun as chief executive officer (CEO) of this wholly owned foreign enterprise. XiBiDi Biotechnology Co. Ltd.’s primary focus is online, retail and direct sales of hemp-based health products in China. Yun’s initial focus in the Company’s first quarter has been the launch of the XiBiDi Magic Hemp Series (“CBD Magic Hemp Series”) cosmetics line which included the registration and approval process with the Chinese FDA for the line’s three initial products. As of the date of this filing the Company completed the registration and approval process with the Chinese FDA for the initial three products in the line and made a key hire to influence the market and assist with marketing and branding in China. The CBD Magic Hemp Series line is different from other skin care lines currently available in China because the products are infused with hemp extract, A catalogue provided by the CFDA entitled “Catalogue of Cosmetics Raw Materials in Use (2015)” includes Cannabis Sativa Leaf Extract.

 

In November 2017, CBD Biotechnology Co. Ltd., teamed up with Chinese beauty influencer, The Godfather of Beauty , for the launch of its “CBD Magic Hemp Series” skincare line on China’s largest e-commerce retailer Alibaba. The Company’s flagship store, the "CBD Enterprise Store," is on Alibaba’s Taobao Platform. The Godfather of Beauty is an Internet celebrity with years of experience in live, online marketing on the Taobao Platform.

 

In November 2017, CBD Biotechnology Co. Ltd. announced the expansion of its consumer division to enter the lucrative liquor (baijiu) market in China. On November 7, 2017, CBD Biotechnology was issued Wholesale Alcohol License from the ShangHai Wine Monopoly Bureau effective October 24, 2107 for a three-year term, which allows CBD Biotechnology to act as a distributor of the baijau. CBD Biotechnology entered into a wholesale agreement with China GuiZhou HanTai Wine, Inc. to distribute its baijui, Yantai 1985, and kicked off its sales and marketing plan by partnering with Jinri Toutiao (translation: Today’s Headlines), a popular Chinese mobile application. The Company announced plans to spin off CBD Biotechnology at the end of February 2018; however, the Company’s Board of Directors has recently approved postponing the spin-off until the Company’s fiscal year end May 31, 2018.

 

ChineseHempOil.com, Inc.

  

In April 2017, the Company established ChineseHempOil.com, Inc. dba “Chinese Wellness Center” a Delaware corporation, as a subsidiary of the Company. ChineseHempOil.com, Inc. responsible for the development and operation of the online and retail sales of non-industrial hemp-based health products in the United States. Chinese Wellness Center is the retail store located in the predominantly Chinese community of San Gabriel, California, located next to the Company’s headquarters. The Company’s first product line OptHemp, is a premium, private label oil, made from full-spectrum, Colorado grown, GMO-Free, non-industrial hemp, manufactured using a CO2 Extraction process.

 

In November 2017, ChineseHempOil.com, Inc. launched its OptHemp product line on Amazon.com kicking off a multi-channel campaign geared to both the US and Chinese-American markets during the 9th annual Singles Day Celebration. This launch commenced the e-commerce marketplace initiative that the Company set into motion in early June through a strategic partnership with a top 100 platinum level partner seller on Amazon Marketplace that agreed to include the OptHemp product line in its limited catalog for resale through the Amazon Channel. This partnership brings to the OptHemp product line, the full weight and power of a national sales and marketing agency that specializes in providing business solutions including headquarter sales services, analytics, insights and intelligence, retail services, marketing, digital technology and business process outsourcing. The Company announced plans to spin off ChineseHempOil.com, Inc. at the end of February 2018; however, the Company’s Board of Directors has recently approved postpoming the spin-off until the Company’s fiscal year end, May 31, 2018.

 

 

 

 

  17  
 

 

Business Environment and Trends

 
The global marketplace has been gradually recovered. We understand that our business is dependent upon the health of the financial markets as well as the financial health of the participants in those markets. With the recovery of the financial market, more market participants willing to subscribe our financial market analysis programs and public companies eager to spend more on increasing media exposure and developing investor relations. 

 

For three and six months ended November 30, 2017 compared to three and six months ended November 30, 2016

 

Quarterly Revenues and Expenses

 

Subscription Revenue: For the three months ended November 30, 2017 and 2016, revenues were $179,333 and $232,094 respectively. For the six months ended November 30, 2017 and 2016, subscription revenues were $315,596 and $481,323 respectively, the decrease in revenue was due to lesser renewal from existing subscriber and lesser new subscribers.

 

Investor Relations-advertisement Revenue: For the three months ended November 30, 2017 and 2016, revenues were $246,667 and $278,850 respectively. The slight decrease of $32,183 is due to the Company provided more services to clients for the three months period ended November 30, 2016 which generated more revenue. For the six months ended November 30, 2017 and 2016, revenues were $505,053 and $369,162 respectively, the increase of $135,871 is due to the Company having hired more professionals in US to service public company clients and increased the service qualities.

 

Other Revenue: For the three months ended November 30, 2017 and 2016, revenues were $0 and $4,754 respectively. For the six months ended November 30, 2017 and 2016, other revenues were $0 and $1,783 respectively, for a decrease of $1,783.

 

Sales-Hemp Related Products: For the three months ended November 30, 2017 and 2016, revenues were $39,603 and $0 respectively. For the six months ended November 30, 2017 and 2016, revenues were $57,568 and $0 respectively. The increase was due to the Company started to sell Hemp-related products.

 

Cost of Service:  Cost of services for the three months ended November 30, 2017 and 2016 were $385,588 and $220,525 respectively, for an increase of $165,063 over the same period in 2016. For the six months ended November 30, 2017 and 2016 were $658,219 and $449,396 respectively, for an increase of $208,823 over the same period in 2016. Both increases were due to its operations in the People’s Republic of China was increased. Cost of products for the three months ended November 30, 2017 and 2016 were $15,050 and $0 respectively. For the six months ended November 30, 2017 and 2016 were $19,951 and $0 respectively. Both increases were due to the Company started to sell Hemp-related products.

 

Gross profit margin: The Company’s gross profit margin on service revenue decreased to 9% ($40,411 on $425,999 of revenue) in the three months ending November 30, 2017 from 57% ($290,419 on $510,944 of revenue) in the three months ending November 30, 2016. The Company’s gross profit margin on service revenue decreased to 20% ($162,410 on $820,029 of revenue) in the six months ending November 30, 2017 form 47% ($402,872 on $852,268 of revenue) in the six months ending November 30, 2016. Both decreases due to the Company’s cost of service increase, the Company issued bonus to Shanghai employees. The Company’s gross profit margin on product sales is 62% ($24,552 on $39,602 of revenue) for the three months ending November 30, 2017. The Company’s gross profit margin on product sales is 65% ($37,617 on $57,568 of revenue) for the six months ending November 30, 2017.

 

General & Administrative Expenses: For the three months ended November 30, 2017 and 2016, expenses were $1,887,872 and $1,207,803, respectively for an increase of $680,069 which was related to additional staff and stock compensation issued for the past services. For the six months ended November 30, 2017 and 2016, expenses were $3,109,803 and $2,053,478, respectively for an increase of $1,056,325 which was related to additional staff and professional service expenses for the company’s operation.

 

Advertising Expenses: For the three months ended November 30, 2017 and 2016, expenses were $303,977 and $180,844 respectively. The increase is due to the Company increased adverting news coverage in many different cities and different languages. For the six months ended November 30, 2017 and 2016, expenses were $529,219 and $361,567 respectively. These expenses are generally related to outside advertising costs and various other related expenses.

 

Net realized gain (loss) on marketable securities: For the three months ended November 30, 2017 and 2016, expenses were $0 and $883,807 respectively. For the six months ended November 30, 2017 and 2016, expenses were $0 and $1,634,685 respectively. There is no liquidation of the Companies holdings in Medicine Man Technologies, Inc. stock.

 

 

 

 

 

  18  
 

  

Liquidity

 

The Company is currently addressing its liquidity concerns by building upon its revenue generating subscription service products, increasing its advertising based revenues, increasing its offerings of other consulting services, and sale of Hemp related products. Since inception in 1997, the Company has at times relied primarily upon proceeds from private placements and sales of shares of its equity securities to fund its operations. In the last two years the Company raised $5,000,043 through the issuance of its Series C-2016 convertible preferred stock. The Company is currently engaged in a private placement of its Series D-2017 convertible preferred stock, the Company has received $2,750,000 from various investors. We anticipate continuing to rely on sales of our securities as well as increasing our general revenues in order to continue to fund our business operations. In addition, the Company liquidated most of its holdings in Medicine Man Technologies (MDCL) stock generating approximately $3,300,000 cash. As of November 30, 2017, the Company still held 41,238 shares of MDCL stock representing $69,691 of value based upon the closing market price of $1.69.

 

Plan of Continued Operations

 

The Company plans to continue to meet all of its obligations as well as conform with all of the requirements of remaining a fully reporting public company while increasing its market presence as well as services offering spectrum.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

The information required by this item is included in Part I Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations" and is incorporated herein by reference.

 

Item 4. Controls and Procedures

 

Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Interim Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

 

 

 

 

  19  
 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is not a party to any legal proceeding that it believes will have a material adverse effect upon its business or financial position.

 

Item 1A. Risk Factors.

 

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

There have been no defaults upon senior securities.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Exhibit 31.1     Certification of the Chief Executive Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2     Certification of Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1     Certification pursuant to Section 906 Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).
101.INS     XBRL Instance Document
101.SCH     XBRL Schema Document
101.CAL     XBRL Calculation Linkbase Document
101.DEF     XBRL Definition Linkbase Document
101.LAB     XBRL Label Linkbase Document
101.PRE     XBRL Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

  20  
 

 

Signatures

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ChineseInvestors.com, Inc.  
  (Registrant)  
       
Date: January 16, 2018 By: /s/ Paul Dickman  
    Paul Dickman  
    Chief Financial Officer  
       
Date: January 16, 2018 By: /s/ Wei Wang  
    Wei Wang  
    Chief Executive Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  21